AUL
ALNY icon

AlphaGrep UK Ltd’s Alnylam Pharmaceuticals ALNY Stock Holding History

AlphaGrep UK Ltd’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$318K Sell
961
-895
-48% -$305K 0.09% 477
2025
Q4 		$738K Buy
+1,856
New +$821K 0.25% 84

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlphaGrep UK Ltd's ALNY Position: Q1 2026 in Review

AlphaGrep UK Ltd reduced its Alnylam Pharmaceuticals (ALNY) stake by 48% in Q1 2026, selling an estimated $305K and leaving 961 shares worth $318K. The position accounts for 0.09% of the portfolio, ranked #477.

AlphaGrep UK Ltd first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. The position peaked at $738K in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • AlphaGrep UK Ltd held 961 shares of Alnylam Pharmaceuticals worth $318K as of Q1 2026.
  • AlphaGrep UK Ltd sold 895 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $305K.
  • Alnylam Pharmaceuticals made up 0.09% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #477 holding.
  • AlphaGrep UK Ltd first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • AlphaGrep UK Ltd's Alnylam Pharmaceuticals position peaked at $738K in Q4 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.